Boehringer Mannheim Gmbh

Roche Diagnostics Gmbh

Winfried Albert

Helmut Lenz

Herbert Jungfer

Josef Endl

Hans-Georg Batz

Joachim Ziegenhorn

Joachim Siedel

Michael Brandt

Brigitte Pautz

Ulrich Neumann

Rosemarie Kientsch-Engel

Wiltrud Richter

Hartmut Schetters

Heinrich Barchet

Werner Scherbaum

Thomas Eiermann

Dolores Schendel

Christa Hubner-Parajsz

August W Wahlefeld

Fritz Stahler

Walter Eberle

Peter Stahl

Hans-Ralf Linke

Bela Molnar

Brigitte Draeger

Kurt W Naujoks

Karl Wulff

Michael Nelbock-Hochstetter

Martin Gerber

Martina Junius

Jurgen Horn

Hinrich Johann Abken

Hans-George Batz

Guenther-Gerhard Jung

Rainer Sch&auml;fer

Jurgen Rasch

George R Evanega

Edgar Meinl

Klaus Dornmair

Willie Gerhardt

The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.

Antigen-specific, activated T lymphocytes, detection and use

A method for culturing and/or multiplying lymphocytes in cell culture medium which contains as lymphocyte growth factor and additionally, aurin tricarboxylic acid, ciclosporin, tacrolimus, and/or ascomycin.

Process for producing and multiplying lymphocytes

The invention addresses DNA-protein-complexes, proteins, DNA sequences and antibodies that are suitable for the detection of cells with an unlimited proliferation and tumor-formation potential. The invention further addresses methods for obtaining such proteins or DNA sequences and methods for identifying animal and human cells with with an unlimited proliferation and tumor-formation potential using such proteins, DNA sequences or antibodies.

Method for identifying human and animal cells having an unlimited proliferation of tumor-formation potential

Automated, microscope-assisted examination process of tissue or bodily fluid samples

The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc &ggr; and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells. The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.

Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof

The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc .gamma. and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells. The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.

Monoclonal antibodies against human pancreatic islet cells

The present invention provides a human monoclonal antibody against melanoma, characterized in that it binds to the gangliosides GM3 and GD3 but essentially does not bind to the gangliosides GM1, GM2, GD1a, GD1b and GD2, the binding of the antibody to the gangliosides having been determined by immune staining after thin layer chromatographic separation of the gangliosides. The present invention also provides a process for the production of human monoclonal antibodies directed against melanoma, wherein, without previous immunization, B-lymphocytes are isolated from a healthy person, the isolated B-lymphocytes are immortalized, antibodies from the immortalized B-lymphocytes are screened by immune-histochemical analysis for binding against melanoma and/or melanoma metastases, the positively reacting B-lymphocytes are selected, cultured and monoclonal antibodies obtained therefrom.

Monoclonal antibodies against melanoma

The present invention provides a process for the specific determination of pancreatic alpha-amylase in the presence of salivary alpha-amylase in body fluids, especially in serum, plasma, duodenal juice or urine, by reaction with a system for the detection of alpha-amylase in the presence of a monoclonal antibody which inhibits salivary alpha-amylase wherein, as inhibitor, there is used a first monoclonal antibody which specifically inhibits the salivary enzyme by less than 97%, in combination with a second monoclonal anti-saliva alpha-amylase antibody which inhibits this enzyme by less than 10%. The present invention also provides a reagent for the specific determination of pancreatic alpha-amylase in the presence of salivary alpha-amylase in body fluids, especially in serum, duodenal juice, plasma or urine, containing a system for the detection of alpha-amylase and a monoclonal antibody against salivary alpha-amylase wherein it contains a first monoclonal antibody which specifically inhibits the salivary enzyme by less than 97%, in combination with a second monoclonal anti-salivary alpha-amylase antibody which inhibits this enzyme by less than 10%.

Process and reagent for specific determination of pancreatic alpha

A method for obtaining permanently culturable human and animal cell lines, as well as uses for these cell lines, are disclosed. The method involves fusing cells of a non-immortal cell line with cytoplasts or cytoplasma fractions of 'immortal', transformed cells such as immortal myeloma cells, ascites-tumor cells or Epstein Barr Virus infected cells. Once fusion takes place the product is a permanently culturable variant of the previously normal cell line.

Process for the production of permanently culturable animal and human

A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behaviour to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample. The standard and a reagent kit for carrying out the process are also the subject of this application.

Process for the quantification of cell populations or subpopulations and

In body fluids containing saliva alpha amylase and pancreatic alpha amylase, pancreatic alpha amylase is determined with a monoclonal antibody which specifically binds but does not inhibit saliva alpha amylase and which has a cross-reactivity of 5% or less toward pancreatic alpha amylase. The monoclonal antibody binds salvia alpha amylase to form a complex which is separated to permit determining pancreatic alpha amylase with an amylase detection system. The complex may be separated by precipitating with a precipitating agent such as an anti-antibody or protein A, or by immobilizing the monoclonal antibody on a solid carrier. The monoclonal antibody is preferably produced by immunizing a host animal with an immunogen containing aluminum hydroxide, Bordatella pertussis and native saliva alpha amylase at least 7 times over a period of at least 9 months, fusing B lymphocytes of the immunized host animal with a transforming agent to produce hybridomas, cloning and culturing the hybridomas, and screening antibodies formed.

Process and monoclonal antibody for the specific determination of

A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behavior to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample. The standard and a reagent kit for carrying out the process are also the subject of this application.

The present invention provides a process for determining the binding capacity of thyroxin-binding globulin (TBG) according to the principle of heterogeneous enzyme immunoassay, wherein the serum sample to be investigated is incubated with enzyme-labelled T.sub.4 or T.sub.3 and immobilized antibody against TBG or T.sub.4, the phase are separated and the labelling enzyme is measured in one of the phases.

Process for determining the binding capacity of thyroxin-binding globulin

Method for the determination of a component of the reaction between a specific binding protein and a substance bindable therewith which process comprises incubating a sample solution with a determined amount of binding component in insoluble form in the presence of a reagent containing a known amount of one of the binding components in enzyme-labeled form, separating the liquid phase from the solid phase by centrifuging and determining the activity of the enzyme remaining in the liquid phase in a centrifuge rotor during or after the action of increased gravitional force whereby the solid phase and the liquid phase are still in contact with one another. The present invention provides a process for the determination of a component of the reaction between a specific binding protein and a substance bindable therewith by incubation of a sample solution with a previously ascertained amount of binding component in insoluble form in the presence of a reagent which contains a known amount of one of the binding components in enyzme labeled form, separation of the liquid phase from the solid phase by centrifuging and determination of the activity of the marker enzyme remaining in the liquid phase, wherein measurement of the enzyme activity is carried out in a centrifuge rotor during or after the action of increased gravitational force whereby the solid phase and the liquid phase are still in contact with one another.

Method for enzyme immuno-determinations in heterogeneous phase

The present invention provides a creatinine antibody and a process for the preparation thereof, wherein a conjugate of creatinine and a material suitable for antiserum formation, which are connected via an aliphatic or araliphatic carboxylic acid as bridge member, is used as immunogen for antiserum formation. The present invention is also concerned with the use of the above antibody for the immunological determination of creatinine, wherein the antibody is incubated with a creatinine-containing sample solution, reacted with a conjugate of creatinine with a hapten carrier substance, whereby one of the components, antibody and conjugate, is present in the solid phase or in dissolved form and the other component is present in dissolved form and the inhibition of the binding reaction between the antibody and the creatinine conjugate is measured. Furthermore, the present invention provides a reagent for the immunological determination of creatinine, wherein it contains the above antibody, a conjugate of creatinine with a hapten carrier substance and buffer substance.

Creatinine antibody

Growing community of inventors

Eberfing, Germany

Winfried Albert